AFFLINK Strengthens Membership With Addition of IPS Packaging & Automation
Partnership Reinforces Company’s Focus on Being the “Home for the Independent™” TUSCALOOSA, Ala.–(BUSINESS WIRE)–#afflink–AFFLINK, a…
Month: March 2023
MozFest 2023: Activism, Whistleblowers, and the Collective Power of People
Chris Smalls, Angela Davis, Thomas le Bonniec, and others will speak at MozFest virtual from…
Scrub In & Rock Out: Surgeons Preview Highway to Heal Album and World’s First AI Healthcare Radio Station at NextMed Health
Lifesaving Radio to stream AC/DC-inspired, customized Operating Room playlists, clinically designed to improve surgical performance…
ModalAI, Inc. VOXL® 2 Announced as Finalist for AUVSI XCELLENCE Awards
Awards ceremony to be held at AUVSI XPONENTIAL 2023 in Denver, CO. SAN DIEGO–(BUSINESS WIRE)–#BlueUASFramework–ModalAI’s…
Ault Alliance Subsidiary Achieves Bitcoin Mining Production Milestone of 1,000 Bitcoin Mined to Date at Its Michigan Data Center
LAS VEGAS–(BUSINESS WIRE)–$AP #1000_Bitcoin_Mined—Ault Alliance, Inc. (NYSE American: AULT), a diversified holding company (“Ault Alliance”…
OKYO Pharma Limited Prices $5.3 Million Offering of ADSs
LONDON, March 13, 2023 (GLOBE NEWSWIRE) — OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (“OKYO…
CRISPR Therapeutics Announces Transition of Chief Financial Officer
ZUG, Switzerland and BOSTON, March 13, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a…
Zynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securities at Silicon Valley Bank
DEVON, Pa., March 13, 2023 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader…
Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements
Engaging with more than two-thirds of key optometrists and/or ophthalmologists, and top payers on Demodex…
TScan Therapeutics to Participate in the Barclays Global Healthcare Conference
WALTHAM, Mass., March 13, 2023 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage…
Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2023, and Recent Developments
— Recorded Third Quarter Revenue of $38.0 Million, a 21% Increase Compared to Prior Year…
Viracta Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
Pivotal NAVAL-1 study of Nana-val in Epstein-Barr virus-positive (EBV+) lymphoma open at 70 sites globally;…
T2 Biosystems Announces Fourth Quarter and Full Year 2022 Financial Results
Achieved record sepsis product revenue and sepsis-driven T2Dx Instrument placements in 2022 LEXINGTON, Mass., March…
TorWallet Generates the Solution for Privacy in Cryptocurrency Transactions
London, United Kingdom–(Newsfile Corp. – March 13, 2023) – TorWallet is pleased to announce the…
Budget Saudi Records Historic Profits in 2022 Driven by Strong Demand and Fleet Expansion
Jeddah, Saudi Arabia–(Newsfile Corp. – March 13, 2023) – Budget Saudi, one of the leading…
CareQuest Innovation Partners and MATTER Launch Second Edition of SMILE Health to Advance Innovation for Accessible, Equitable, and Integrated Oral Care
The program seeks early-stage startups for a 12-week program driving business development BOSTON & CHICAGO–(BUSINESS…
TechTarget Dramatically Enhances Intent Data Actionability with Confirmed Projects to Make Tech Sales Teams More Productive Immediately
Confirmed Projects available within TechTarget’s Priority Engine provide full visibility into verified technology purchases &…
Citizens Extends Branch Hours to Further Serve Customers and Communities
PROVIDENCE, R.I.–(BUSINESS WIRE)–Given recent market developments, Citizens has seen higher than normal interest from prospective…
AB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001)
PRESS RELEASE AB SCIENCE REPORTS A FIRST COMPLETE BONE MARROW RESPONSE IN A RELAPSED REFRACTORY…
AB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001)
PRESS RELEASE AB SCIENCE REPORTS A FIRST COMPLETE BONE MARROW RESPONSE IN A RELAPSED REFRACTORY…